Products
Anoxiton
Pharmacotherapeutic group
Other agents used in gynecologyInternational name
AtozibanDosage form
concentrate for preparation of solution for infusionThe drug Anoxiton contains atoziban, a synthetic peptide ([Mra1, D-Tyr(Et)2, Thr4, Ogp8-oxytocin). By binding to human oxytocin receptors, atoziban is a competitive antagonist of human oxytocin. In preclinical studies it was shown that atoziban, interacting with oxytocin receptors, reduces the frequency of uterine contractions and myometrial tone, which leads to suppression of uterine contractility. Atoziban also binds to vasopressin receptors, thus inhibiting its action. In preclinical studies, no evidence of atoziban's effect on the cardiovascular system was found.
In case of preterm labor in a woman, atoziban in recommended doses suppresses uterine contractions and provides the uterus with functional rest.
Relaxation of the uterus after atoziban administration is achieved quickly, within 10 min myometrial contractile activity is significantly reduced, maintaining stable functional rest of the uterus (< 4 contractions per hour) for 12 hours.
In case of preterm labor in a woman, atoziban in recommended doses suppresses uterine contractions and provides the uterus with functional rest.
Relaxation of the uterus after atoziban administration is achieved quickly, within 10 min myometrial contractile activity is significantly reduced, maintaining stable functional rest of the uterus (< 4 contractions per hour) for 12 hours.